TWI787898B - Composition for forming soft capsules, delayed-dissolving soft capsules using the same, and capsule-type human tissue lubricating suppositories - Google Patents
Composition for forming soft capsules, delayed-dissolving soft capsules using the same, and capsule-type human tissue lubricating suppositories Download PDFInfo
- Publication number
- TWI787898B TWI787898B TW110124565A TW110124565A TWI787898B TW I787898 B TWI787898 B TW I787898B TW 110124565 A TW110124565 A TW 110124565A TW 110124565 A TW110124565 A TW 110124565A TW I787898 B TWI787898 B TW I787898B
- Authority
- TW
- Taiwan
- Prior art keywords
- soft capsule
- composition
- capsule
- forming
- human tissue
- Prior art date
Links
Images
Landscapes
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本發明係揭露一種軟質膠囊形成用組成物,該軟質膠囊形成用組成物至少包括:10 wt%至50 wt%的明膠;0.1wt%至30 wt%的增塑劑;5wt%至50 wt%的保水劑;0.01 wt%至20 wt%的增稠劑;0.1wt%至10wt%的助流劑;0.1wt%至10wt%的崩解劑;5 wt%至40 wt%的水。利用該軟質膠囊形成用組成物所製成的軟質膠囊能夠安全放置於人體組織內、且在中溫高溼度偏酸環境下能夠於一指定時間之範圍內完全溶解。將潤滑劑填充於該軟質膠囊之中還能夠進一步製成膠囊型人體組織潤滑用栓劑。The present invention discloses a composition for forming a soft capsule, the composition for forming a soft capsule at least includes: 10 wt% to 50 wt% gelatin; 0.1 wt% to 30 wt% plasticizer; 5 wt% to 50 wt% 0.01wt% to 20wt% thickener; 0.1wt% to 10wt% glidant; 0.1wt% to 10wt% disintegrant; 5wt% to 40wt% water. The soft capsule made by using the soft capsule forming composition can be safely placed in human tissue, and can be completely dissolved within a specified time range in a medium-temperature, high-humidity, acidic environment. Filling the lubricant into the soft capsule can further make a capsule type human tissue lubricating suppository.
Description
本發明是有關於一種膠囊殼體,特別是有關於一種用於容納潤滑劑之膠囊殼體。The present invention relates to a capsule casing, in particular to a capsule casing for containing lubricant.
一般來說,習知用於人體肌膚之潤滑劑均是容置於罐裝、瓶裝或其他容器,待使用時,以傾倒、擠壓等方式將潤滑劑由容器中取出。然,此種容置方式,常見地具有下列問題:Generally speaking, conventionally used lubricants for human skin are contained in cans, bottles or other containers, and the lubricants are taken out from the containers by pouring, squeezing, etc. before use. However, this kind of accommodating method usually has the following problems:
1、於取出潤滑劑使用時,若手部清潔不夠或重複執行取出動作時,有可能將細菌病毒帶入人體,進而產生感染的風險,於衛生安全上形成疑慮。1. When taking out the lubricant for use, if the hands are not clean enough or the taking-out action is repeated, bacteria and viruses may be brought into the human body, thereby causing the risk of infection and causing doubts in terms of hygiene and safety.
2、由於潤滑劑是存放於容器中,故在攜帶上較為不便,另在使用過程中,容器可能佔有一定體視覺上較為突兀,此外在使用方式上,須經由取出步驟才能使用,易造成使用體驗上產生不好觀感。2. Since the lubricant is stored in the container, it is inconvenient to carry. In addition, during use, the container may occupy a certain volume, which is visually awkward. In addition, in the use method, it must be taken out before use, which is easy to cause use. A bad impression on the experience.
其中,中華明國專利TW M544316係關於一種水性組成物之容器結構及壓力式容器,其包含一瓶體,具有一子彈型容置空間,該子彈型容置空間用於容納包括一蘆薈萃取液及一玻尿酸的一水性組成物,其中,當該瓶體受一壓力時,該水性組成物係流出該瓶體。Among them, the patent TW M544316 of the Ming Dynasty of China is related to a container structure and a pressure container of a water-based composition, which includes a bottle body and a bullet-shaped accommodation space, which is used to accommodate an aloe extract And an aqueous composition of hyaluronic acid, wherein, when the bottle is subjected to a pressure, the aqueous composition flows out of the bottle.
中華民國專利TW M526400係關於一種胃崩膠囊劑型,其具有一胃容性膠囊外殼;以及天然活性胜肽粉末層,被填充於該胃溶性膠囊外殼內。The patent TW M526400 of the Republic of China relates to a dosage form of stomach-disintegrating capsules, which has a stomach-capacity capsule shell; and a natural active peptide powder layer, which is filled in the stomach-soluble capsule shell.
中國專利CN103598971A係關於一種具有潤滑功能的電動情趣用品,其包含驅動部分、潤滑部分、控制部分及模擬器官,其中驅動部分可帶動模擬器官模仿人類自然運動,而潤滑部分則可有效儲存潤滑液,並可藉由泵抽取潤滑液進而由連通管導入模擬器官之中,當人體進入模擬器官中則可達到潤滑之效果。Chinese patent CN103598971A relates to an electric sex toy with lubricating function, which includes a driving part, a lubricating part, a control part and a simulated organ, wherein the driving part can drive the simulated organ to imitate the natural movement of humans, while the lubricating part can effectively store lubricating fluid. The lubricating fluid can be drawn by the pump and then introduced into the simulated organ through the connecting tube. When the human body enters the simulated organ, the lubricating effect can be achieved.
中國專利CN104352679A係關於一種潤腸通便膠囊,包括膠囊內的中草藥提取物和凝膠外殼,其進一步揭露中草藥提取物之原料為蘆薈提取物、火麻仁、莱菔子、決明子及杏仁,並揭露凝膠外殼之原料及原料配比為明膠:甘油:乙醇:純化水=3~5%:1%~3%:5~8%:84~91%。此潤腸通便膠囊係具有滑膩感,故可對直腸內壁產生潤滑作用,且膠囊本身係為水溶性。Chinese patent CN104352679A is about a laxative capsule, which includes Chinese herbal medicine extract and gel shell in the capsule. The raw materials and raw material ratio of the gel shell are gelatin: glycerin: ethanol: purified water = 3~5%: 1%~3%: 5~8%: 84~91%. The Runchang Laxative Capsule has a greasy feeling, so it can lubricate the inner wall of the rectum, and the capsule itself is water-soluble.
美國專利US6749557B2係關於一種自潤滑性輔助裝置,係可藉由容置於其中的潤滑液產生潤滑效果,其包含用於裝載潤滑液之空腔,以及將空腔連結至性輔助器的連接機構。性輔助器包含用於接觸使用者之外表面及內表面之表面結構,其係具有一個或多個孔洞;使用者可藉由控制連接機構促使空腔之潤滑液流動至人體。U.S. Patent US6749557B2 relates to a self-lubricating auxiliary device, which can produce a lubricating effect through the lubricating fluid contained therein, which includes a cavity for loading the lubricating fluid, and a connecting mechanism that connects the cavity to the sexual aid . The sexual aid includes a surface structure for contacting the outer surface and the inner surface of the user, which has one or more holes; the user can make the lubricating fluid in the cavity flow to the human body by controlling the connection mechanism.
美國專利US7858119B1係關於一種延長釋放性藥物,其中藥劑係包裹於聚合物膜層內,並可於胃腸道及血漿中逐漸釋放藥物活性物質長達12至24小時。此延長釋放性藥物包含外殼,此外殼係可為單層或多層之聚合物膜,且其需於ph5以上之環境中溶解,關聯專利US7858119B1係進一步揭露外殼係包含0.5~30%的聚乙二醇增塑劑及5~55%的聚合物。US Patent No. 7,858,119B1 relates to a prolonged-release drug, in which the drug is wrapped in a polymer film, and the drug active substance can be gradually released in the gastrointestinal tract and plasma for 12 to 24 hours. The extended-release drug includes a shell, which can be a single-layer or multi-layer polymer film, and it needs to be dissolved in an environment above pH 5. The related patent US7858119B1 further discloses that the shell contains 0.5-30% polyethylene glycol Alcohol plasticizer and 5~55% polymer.
然,上述相關專利前案皆無法解決膠囊殼體於常溫中不受內部潤滑油之侵蝕之問題。However, none of the above-mentioned related patents can solve the problem that the capsule shell is not corroded by the internal lubricating oil at room temperature.
鑑於上述習知之問題,本發明的目的在於提供一種保存潤滑劑用之膠囊,用以解決習知技術中所面臨之問題。In view of the above-mentioned known problems, the object of the present invention is to provide a capsule for storing lubricant to solve the problems faced in the prior art.
基於上述目的,本發明係提供一種軟質膠囊形成用組成物,其特徵在於:用以形成可安全放置於人體組織內、且在中溫高溼度偏酸環境下能夠於一指定時間之範圍內完全溶解的軟質膠囊,該軟質膠囊形成用組成物至少包括:10 wt%至50 wt%的明膠;0.1wt%至30 wt%的增塑劑;5wt%至50 wt%的保水劑;0.01 wt%至20 wt%的增稠劑;0.1wt%至10wt%的助流劑;0.1wt%至10wt%的崩解劑;5 wt%至40 wt%的水;其中在該軟質膠囊形成用組成物中,該增塑劑與增稠劑的乾品總量相對於明膠乾品重量的比值為在0.01至5.0之間;該軟質膠囊形成用組成物的黏度為在10~45厘泊之間、凝膠強度為在150~2500 Bloom之間;以及該軟質膠囊形成用組成物固化後所得到的該軟質膠囊放置於人體組織內的中溫高溼度偏酸環境下能夠在5.0至15min之範圍內完全溶解。Based on the above purpose, the present invention provides a composition for forming soft capsules, which is characterized in that: it is used to form a soft capsule that can be safely placed in human tissue and can be completely completely within a specified time in a medium-temperature, high-humidity, acidic environment. A dissolved soft capsule, the composition for forming the soft capsule at least includes: 10 wt% to 50 wt% gelatin; 0.1 wt% to 30 wt% plasticizer; 5 wt% to 50 wt% water retaining agent; 0.01 wt% 0.1wt% to 10wt% glidant; 0.1wt% to 10wt% disintegrant; 5wt% to 40wt% water; Among them, the ratio of the total amount of dry product of the plasticizer and the thickener to the weight of the dry product of gelatin is between 0.01 and 5.0; the viscosity of the composition for forming the soft capsule is between 10 and 45 centipoise, The gel strength is between 150 and 2500 Bloom; and the soft capsule obtained after the composition for forming the soft capsule is solidified can be placed in a medium-temperature, high-humidity, acidic environment in human tissue within the range of 5.0 to 15 minutes completely dissolved.
根據本發明之一實施例,該增塑劑為選自甘油、二羧酸/三羧酸酯類、己二酸酯類、癸二酸酯類、馬來酸酯類苯甲酸酯類、磺醯胺類、乙醯單酸甘油乙酯、三仙膠、檸檬酸酯及環己烷-1,2-二羧酸二異壬酯中之至少一種。According to one embodiment of the present invention, the plasticizer is selected from glycerin, dicarboxylic acid/tricarboxylic acid esters, adipate, sebacate, maleate benzoate, sulfonate At least one of amides, ethyl acetyl monoglyceride, sanxian gum, citric acid ester and diisononyl cyclohexane-1,2-dicarboxylate.
根據本發明之一實施例,該保水劑為選自磷酸鹽類、多元醇、甜菜鹼、NaPCA、玻尿酸、鎖水磁石、黏多醣及泛醇中之至少一種。According to an embodiment of the present invention, the water retaining agent is at least one selected from the group consisting of phosphates, polyols, betaine, NaPCA, hyaluronic acid, magnetite, mucopolysaccharide and panthenol.
根據本發明之一實施例,該增稠劑為選自由無機鹽類增稠劑、脂肪醇類增稠劑、脂肪酸類增稠劑、烷醇酰胺類增稠劑、烷醇酰胺類增稠劑、醚類增稠劑、酯類增稠劑、氧化醇胺類增稠劑、纖維素類增稠劑、聚丙烯酸類增稠劑、聚胺基甲酸酯類增稠劑、聚氧乙烯類增稠劑、及天然膠類增稠劑、羥乙基纖維素及皂類增稠劑中之至少一種;更佳為。According to one embodiment of the present invention, the thickener is selected from inorganic salt thickeners, fatty alcohol thickeners, fatty acid thickeners, alkanolamide thickeners, alkanolamide thickeners , ether thickener, ester thickener, oxidized alcohol amine thickener, cellulose thickener, polyacrylic thickener, polyurethane thickener, polyoxyethylene thickener Thickener, and at least one of natural rubber thickener, hydroxyethyl cellulose and soap thickener; more preferably.
根據本發明之一實施例,該助流劑為選自抗壞血酸棕櫚酸酯、棕櫚酸鈣、硬脂酸鎂、氣相二氧化矽(膠態二氧化矽)、澱粉及石灰粉中之至少一種。According to one embodiment of the present invention, the glidant is at least one selected from ascorbyl palmitate, calcium palmitate, magnesium stearate, fumed silicon dioxide (colloidal silicon dioxide), starch and lime powder .
根據本發明之一實施例,該崩解劑為選自澱粉、羧甲基澱粉鈉、低取代羥丙基甲基纖維素(L-HPC)、交聯聚乙烯吡咯烷酮及泡騰崩解劑中之至少一種。According to one embodiment of the present invention, the disintegrant is selected from starch, sodium carboxymethyl starch, low-substituted hydroxypropyl methylcellulose (L-HPC), cross-linked polyvinylpyrrolidone and effervescent disintegrants at least one of them.
根據本發明之一實施例,該中溫高溼度偏酸環境的pH值為在4~5.8之間、溫度為30~40℃之間、以及濕度為在RH60~RH80之間。According to an embodiment of the present invention, the pH value of the acidic environment with medium temperature and high humidity is between 4-5.8, the temperature is between 30-40° C., and the humidity is between RH60-RH80.
根據本發明之一實施例,該人體組織為陰道、肛門、或直腸附近。According to an embodiment of the present invention, the human tissue is near the vagina, anus, or rectum.
另外,本發明還可以提供一種定時溶解型軟質膠囊,其為由前述軟質膠囊形成用組成物以壓製法或滴製法所製作而成,特徵在於:該定時溶解型軟質膠囊為單層結構、或兩層以上之多層結構,各單層厚度為在0.02~1.50mm,總厚度為在0.25~1.50mm之間;該定時溶解型軟質膠囊放置於人體組織內的中溫高溼度偏酸環境條件下能夠在5.0至15min之範圍內完全溶解。In addition, the present invention can also provide a time-dissolving soft capsule, which is made from the above-mentioned composition for forming soft capsules by a compression method or a dripping method, and is characterized in that: the time-dissolving soft capsule has a single-layer structure, or Multi-layer structure with more than two layers, the thickness of each single layer is 0.02~1.50mm, and the total thickness is between 0.25~1.50mm; the time-dissolving soft capsule is placed in the human tissue under the condition of medium temperature, high humidity and acidic environment It can be completely dissolved in the range of 5.0 to 15 minutes.
又,本發明亦可以提供一種膠囊型人體組織潤滑用栓劑,其特徵在於:包含在由前述組成物所製成的軟質膠囊、或利用如前述之製備方法所製得的軟質膠囊中填充一矽基潤滑劑或水系潤滑劑。本實施例中所使用的該潤滑劑至少包括:42~76wt%的環戊矽氧烷;18~42wt%的二甲基矽氧烷醇;6~16wt%的聚二甲基矽氧烷。又,該矽基潤滑劑也可以進一步含有6 wt%至16 wt%的水。Moreover, the present invention can also provide a capsule-type human tissue lubricating suppository, which is characterized in that: a soft capsule made of the aforementioned composition or a soft capsule made by the aforementioned preparation method is filled with silicon base lubricant or water-based lubricant. The lubricant used in this embodiment at least includes: 42-76wt% cyclopentasiloxane; 18-42wt% dimethiconol; 6-16wt% polydimethylsiloxane. Also, the silicon-based lubricant may further contain 6 wt% to 16 wt% of water.
另外,本實施例中所使用的該水系潤滑劑較佳為至少包含有0.1~2.5wt%的三仙膠、0.1~4wt%的羥乙基纖維素、0.1~10wt%的甘油、0.001~10wt%玻尿酸、0.01~8wt%的鎖水磁石、檸檬酸0.01~3wt% 、0.01~4wt%的檸檬酸/氫氧化鈉、1~8wt%的戊二醇、以及6~97wt%的純水。In addition, the water-based lubricant used in this embodiment preferably contains at least 0.1-2.5wt% Sanxian gum, 0.1-4wt% hydroxyethyl cellulose, 0.1-10wt% glycerin, 0.001-10wt% % hyaluronic acid, 0.01~8wt% water-locking magnet, 0.01~3wt% citric acid, 0.01~4wt% citric acid/sodium hydroxide, 1~8wt% pentylene glycol, and 6~97wt% pure water.
承上所述,本發明之保存潤滑劑用之膠囊藉由膠囊殼體於同時符合溶解酸鹼值範圍、溶解溫度範圍及溶解濕度範圍時會溶解之特性,以使容置於膠囊殼體內之潤滑劑得以作用在人體上,而產生潤滑的效果。Based on the above, the capsule for storing lubricants of the present invention has the characteristics that the capsule shell will dissolve when it meets the range of the dissolution pH value, the dissolution temperature range, and the dissolution humidity range, so that the capsules contained in the capsule shell Lubricants can act on the human body to produce a lubricating effect.
以下,針對本發明的實施態樣列舉各種不同的具體實施例而更加詳盡地敘述與說明,以便使本發明的精神與內容更為完備而易於瞭解;然而,本項技藝中具有通常知識者應當明瞭本發明當然不受限於此等實例而已,亦可利用其他相同或均等的功能與步驟順序來達成本發明。In the following, various specific embodiments are listed for the implementation of the present invention and described and illustrated in more detail so as to make the spirit and content of the present invention more complete and easy to understand; however, those with ordinary knowledge in this art should It is understood that the present invention is of course not limited to these examples, and other same or equivalent functions and step sequences can also be used to achieve the present invention.
在本文中,此處所用的科學與技術詞彙之含義與本發明所屬技術領域中具有通常知識者所理解與慣用的意義相同。此外,在不和上下文衝突的情形下,本說明書所用的單數名詞涵蓋該名詞的複數型;而所用的複數名詞時亦涵蓋該名詞的單數型。In this document, the meanings of scientific and technical terms used herein are the same as those understood and commonly used by those skilled in the art to which the present invention belongs. In addition, the singular nouns used in this specification include the plural forms of the nouns, and the plural nouns used also include the singular forms of the nouns, unless the context conflicts with the context.
在本文中,對於用以界定本發明範圍的數值與參數,本質上不可避免地含有因個別測試方法所致的標準偏差,因而大多是以約略的數量值來表示,然而於具體實施例中則盡可能精確呈現的相關數值。在本文中,「約」通常視本發明所屬技術領域中具有通常知識者的考量而定,一般係指代表實際數值落在平均值的可接受標準誤差之內,例如,該實際數值為在一特定數值或範圍的±10%、±5%、±1%、或±0.5%以內。In this article, for the numerical values and parameters used to define the scope of the present invention, the standard deviations caused by individual test methods are inevitably included in nature, so most of them are expressed in approximate numerical values, but in the specific examples The relevant numerical values are presented as precisely as possible. In this article, "about" usually depends on the consideration of those with ordinary knowledge in the technical field of the present invention, and generally means that the actual value falls within the acceptable standard error of the mean, for example, the actual value is within a Within ±10%, ±5%, ±1%, or ±0.5% of a specified value or range.
請參閱圖1,其係為本發明之膠囊型人體組織潤滑用栓劑之示意圖。如圖1所示,該膠囊型人體組織潤滑用栓劑100包含了軟質膠囊110,軟質膠囊110為一中空殼體,且其內部容置有潤滑劑120;本發明之膠囊型人體組織潤滑用栓劑100可安全放置於人體組織內、且在中溫高溼度偏酸環境下能夠於一指定時間之範圍內完全溶解。軟質膠囊110是利用一軟質膠囊形成用組成物以壓製法或滴製法所製作而成,該軟質膠囊形成用組成物至少包括:10 wt%至50 wt%的明膠;0.1wt%至30 wt%的增塑劑;5wt%至50 wt%的保水劑;0.01 wt%至20 wt%的增稠劑;0.1wt%至10wt%的助流劑;0.1wt%至10wt%的崩解劑;5 wt%至40 wt%的水。又,該軟質膠囊形成用組成物的黏度為在10~45厘泊之間。Please refer to Fig. 1, which is a schematic diagram of the capsule-type human tissue lubricating suppository of the present invention. As shown in Figure 1, the capsule type human
根據本發明的技術思想,該增塑劑為選自甘油、二羧酸/三羧酸酯類、己二酸酯類、癸二酸酯類、三仙膠、馬來酸酯類苯甲酸酯類、磺醯胺類、乙醯單酸甘油乙酯、檸檬酸酯及環己烷-1,2-二羧酸二異壬酯中之至少一種;較佳為選自甘油、二羧酸/三羧酸酯類、己二酸酯類、癸二酸酯類、馬來酸酯類苯甲酸酯類、磺醯胺類、及乙醯單酸甘油乙酯中之至少一種;更佳為選自甘油、二羧酸/三羧酸酯類、己二酸酯類、癸二酸酯類、及馬來酸酯類苯甲酸酯類中之至少一種;最佳為選自甘油、二羧酸/三羧酸酯類、及己二酸酯類中之至少一種。According to the technical idea of the present invention, the plasticizer is selected from glycerin, dicarboxylic acid/tricarboxylic acid esters, adipate esters, sebacate esters, sanxian gum, maleic acid ester benzoate At least one of triglycerides, sulfonamides, ethyl acetyl monoglyceride, citrate and diisononyl cyclohexane-1,2-dicarboxylate; preferably selected from glycerol, dicarboxylic acid/ At least one of tricarboxylic acid esters, adipate esters, sebacic acid esters, maleic acid esters, benzoic acid esters, sulfonamides, and ethyl acetyl monoglyceride; more preferably At least one selected from glycerin, dicarboxylic acid/tricarboxylic acid esters, adipate, sebacic acid ester, and maleic acid ester benzoate; optimally selected from glycerin, dicarboxylic acid /At least one of tricarboxylic acid esters and adipate esters.
根據本發明的技術思想,該保水劑為選自磷酸鹽類、多元醇、甜菜鹼、咯烷酮羧酸鈉(NaPCA, Sodium Pyrrolidone Carboxylate)、玻尿酸、鎖水磁石、黏多醣及泛醇中之至少一種;較佳為選自磷酸鹽類、多元醇、甜菜鹼、及咯烷酮羧酸鈉(NaPCA, Sodium Pyrrolidone Carboxylate)中之至少一種;更佳為選自磷酸鹽類、多元醇、及甜菜鹼中之至少一種。According to the technical idea of the present invention, the water-retaining agent is selected from phosphates, polyols, betaine, sodium rolidone carboxylate (NaPCA, Sodium Pyrrolidone Carboxylate), hyaluronic acid, water-locking magnets, mucopolysaccharides and panthenol. At least one; preferably at least one selected from phosphates, polyols, betaines, and sodium rolidone carboxylate (NaPCA, Sodium Pyrrolidone Carboxylate); more preferably selected from phosphates, polyols, and at least one of betaines.
根據本發明的技術思想,該增稠劑為選自無機鹽類增稠劑、脂肪醇類增稠劑、脂肪酸類增稠劑、烷醇酰胺類增稠劑、烷醇酰胺類增稠劑、醚類增稠劑、酯類增稠劑、氧化醇胺類增稠劑、纖維素類增稠劑、聚丙烯酸類增稠劑、聚胺基甲酸酯類增稠劑、聚氧乙烯類增稠劑、羥乙基纖維素及天然膠類增稠劑、皂類增稠劑中之至少一種;較佳為選自無機鹽類增稠劑、脂肪醇類增稠劑、脂肪酸類增稠劑、烷醇酰胺類增稠劑、烷醇酰胺類增稠劑、醚類增稠劑、酯類增稠劑、氧化醇胺類增稠劑、纖維素類增稠劑、聚丙烯酸類增稠劑、聚胺基甲酸酯類增稠劑、及天然膠類增稠劑中之至少一種;更佳為選自無機鹽類增稠劑、脂肪醇類增稠劑、脂肪酸類增稠劑、烷醇酰胺類增稠劑、酯類增稠劑、氧化醇胺類增稠劑、纖維素類增稠劑、聚丙烯酸類增稠劑、聚胺基甲酸酯類增稠劑、及天然膠類增稠劑中之至少一種;最佳為選自無機鹽類增稠劑、脂肪醇類增稠劑、脂肪酸類增稠劑、酯類增稠劑、纖維素類增稠劑、聚丙烯酸類增稠劑、及天然膠類增稠劑中之至少一種。According to the technical idea of the present invention, the thickener is selected from inorganic salt thickeners, fatty alcohol thickeners, fatty acid thickeners, alkanolamide thickeners, alkanolamide thickeners, Ether thickener, ester thickener, amine oxide thickener, cellulose thickener, polyacrylic thickener, polyurethane thickener, polyoxyethylene thickener At least one of thickeners, hydroxyethyl cellulose and natural gum thickeners, soap thickeners; preferably selected from inorganic salt thickeners, fatty alcohol thickeners, fatty acid thickeners, Alkanolamide thickeners, alkanolamide thickeners, ether thickeners, ester thickeners, oxidized alcohol amine thickeners, cellulose thickeners, polyacrylic acid thickeners, At least one of polyurethane thickeners and natural rubber thickeners; more preferably selected from inorganic salt thickeners, fatty alcohol thickeners, fatty acid thickeners, alkanolamides thickeners, ester thickeners, amine oxide thickeners, cellulose thickeners, polyacrylic thickeners, polyurethane thickeners, and natural rubber thickeners At least one of them; optimally selected from inorganic salt thickeners, fatty alcohol thickeners, fatty acid thickeners, ester thickeners, cellulose thickeners, polyacrylic thickeners, And at least one of natural rubber thickeners.
根據本發明的技術思想,該助流劑為選自抗壞血酸棕櫚酸酯、棕櫚酸鈣、硬脂酸鎂、氣相二氧化矽(膠態二氧化矽)、澱粉及石灰粉中之至少一種;較佳為選自抗壞血酸棕櫚酸酯、棕櫚酸鈣、硬脂酸鎂、氣相二氧化矽(膠態二氧化矽)、及澱粉中之至少一種;較佳為選自硬脂酸鎂、氣相二氧化矽(膠態二氧化矽)、及澱粉中之至少一種;較佳為選自抗壞血酸棕櫚酸酯、棕櫚酸鈣、硬脂酸鎂、及氣相二氧化矽(膠態二氧化矽)中之至少一種。According to the technical idea of the present invention, the glidant is at least one selected from ascorbyl palmitate, calcium palmitate, magnesium stearate, fumed silicon dioxide (colloidal silicon dioxide), starch and lime powder; Preferably at least one selected from ascorbyl palmitate, calcium palmitate, magnesium stearate, fumed silicon dioxide (colloidal silicon dioxide), and starch; preferably selected from magnesium stearate, fumed At least one of phase silicon dioxide (colloidal silicon dioxide), and starch; preferably selected from ascorbyl palmitate, calcium palmitate, magnesium stearate, and fumed silicon dioxide (colloidal silicon dioxide ) at least one of them.
根據本發明的技術思想,該崩解劑為選自澱粉、羧甲基澱粉鈉、低取代羥丙基甲基纖維素(L-HPC)、交聯聚乙烯吡咯烷酮及泡騰崩解劑中之至少一種;較佳為選自澱粉、羧甲基澱粉鈉、及低取代羥丙基甲基纖維素(L-HPC)中之至少一種。According to the technical idea of the present invention, the disintegrant is selected from starch, sodium carboxymethyl starch, low-substituted hydroxypropyl methylcellulose (L-HPC), cross-linked polyvinylpyrrolidone and effervescent disintegrants. At least one; preferably at least one selected from starch, sodium starch glycolate, and low-substituted hydroxypropylmethylcellulose (L-HPC).
再者,在該軟質膠囊形成用組成物中,該增塑劑與增稠劑的乾品總量相對於明膠乾品重量的比值一般為在0.01至5.0之間;較佳為在0.01至4.0之間;更佳為在0.01至3.0之間;最佳為在0.01至1.0之間;藉此,該軟質膠囊形成用組成物固化後所得到的該軟質膠囊放置於人體組織內的中溫高溼度偏酸環境下能夠控制在5.0至15min之指定時間範圍內完全溶解,並且該軟質膠囊的溶解速率能夠控制在0.1g/min至2.0g/min之範圍。Furthermore, in the composition for forming soft capsules, the ratio of the total dry weight of the plasticizer and thickener to the weight of the dry gelatin is generally between 0.01 and 5.0; preferably between 0.01 and 4.0 between; more preferably between 0.01 and 3.0; most preferably between 0.01 and 1.0; thereby, the soft capsule obtained after the soft capsule forming composition is solidified is placed in the human tissue at a high temperature It can be controlled to completely dissolve within a specified time range of 5.0 to 15 minutes under an acidic humidity environment, and the dissolution rate of the soft capsule can be controlled within a range of 0.1 g/min to 2.0 g/min.
如圖1所示之定時溶解型軟質膠囊為單層結構,但並不以此為限,本發明之定時溶解型軟質膠囊也可以是兩層以上之多層結構,各單層厚度為在0.02~1.50mm,總厚度為在0.25~1.50mm之間。The time-dissolving soft capsule shown in Figure 1 is a single-layer structure, but it is not limited to this. The time-dissolving soft capsule of the present invention can also be a multi-layer structure with more than two layers, and each single-layer thickness is 0.02~ 1.50mm, the total thickness is between 0.25~1.50mm.
另外,填充於軟質膠囊110中之潤滑劑120至少包括有42~76wt%的環戊矽氧烷;18~42wt%的二甲基矽氧烷醇;6~16wt%的聚二甲基矽氧烷。藉由潤滑劑120之原料及原料配比可達到穩定存放於膠囊殼體110之中,由於潤滑劑中含水,若水的比例太高便會使得膠囊殼體110軟化,進而將含水比例降到最低程度,在此最低程度指的是需兼顧潤滑劑120之體感效果及功能,而非一昧地要求最低含水比例,因此,一般來說該潤滑劑120還包含有1 wt%至16 wt%的水。In addition, the
於實際使用本發明之保存潤滑劑用之膠囊100時,係將其放置於人體之特定組織之中,例如陰道、肛門、或直腸附近,待膠囊殼體110於所在處之酸鹼值、溫度及濕度符合溶解酸鹼值範圍、溶解溫度範圍及溶解濕度範圍時,膠囊殼體110將開始溶解,容置於膠囊殼體110內之潤滑劑120便會從膠囊殼體110內流出而發揮出潤滑效果。When the
值得一提的是,藉由膠囊殼體110之原料及原料配比可達到於符合溶解溫度範圍及溶解濕度範圍的情境下,膠囊殼體於人體中溶解,另一方面亦可達到在保存環境中不會自然溶解而可穩定保存之功效。It is worth mentioning that the capsule shell can be dissolved in the human body under conditions that meet the dissolution temperature range and dissolution humidity range through the raw materials and raw material ratio of the
接著,以下以具體實施例來說明本發明。 《實施例1至5》 Next, the present invention is described below with specific examples. "Examples 1 to 5"
首先,將明膠與水以如表1所示的重量混合並且均勻攪拌後獲得膠囊基質劑;接著,將如表1所示之重量的甘油、甜菜鹼、甲基纖維素、硬脂酸鎂、及澱粉依序加入膠囊基質劑之中,並且在50℃之溫度條件下攪拌至各成分均勻分散,即可獲得本發明之軟質膠囊形成用組合物S1至S5。利用黏度劑及凝膠強度測定計檢測軟質膠囊形成用組合物S1至S5的黏度及強度,並將數值紀錄於表1。First, mix gelatin and water with the weight shown in Table 1 and obtain the capsule matrix after uniform stirring; then, glycerin, betaine, methylcellulose, magnesium stearate, magnesium stearate, and starch are sequentially added into the capsule base agent, and stirred at a temperature of 50° C. until the components are uniformly dispersed, and then the compositions S1 to S5 for forming soft capsules of the present invention can be obtained. The viscosities and strengths of the compositions S1 to S5 for forming soft capsules were tested with a viscometer and a gel strength meter, and the values were recorded in Table 1.
接著,將軟質膠囊形成用組合物S1至S5均勻塗布在平坦的板表面上,然後用90℃左右的溫度加熱,使其表面水分蒸發而形成軟膠片,在利用旋轉膠囊填充機來使該軟膠片成行為膠囊殼體,並將一人體用之潤滑劑組合物填充至膠囊殼體之中,進而製成軟質膠囊M1至M5。該人體用之潤滑劑組合物可以使用矽基潤滑劑,也可以使用水系潤滑劑。本實施例中所使用的該矽基潤滑劑螭佳為至少包含有42~7wt%的環戊矽氧烷(Cyclopentasiloxane)、18~42wt%的二甲基矽氧烷醇(Dimethiconol)、6~16% 聚二甲基矽氧烷(Dimethicone);又,也可以進一步包括6 wt%至16 wt%的水。Next, the compositions S1 to S5 for forming soft capsules are evenly coated on a flat plate surface, and then heated at a temperature of about 90° C. to evaporate the moisture on the surface to form a soft film. The film is made into a capsule shell, and a lubricant composition for the human body is filled into the capsule shell, thereby making soft capsules M1 to M5. The lubricant composition for the human body can use silicon-based lubricants or water-based lubricants. The silicon-based lubricant used in this embodiment preferably contains at least 42~7wt% of cyclopentasiloxane (Cyclopentasiloxane), 18~42wt% of dimethylsiloxane alcohol (Dimethiconol), 6~ 16% polydimethylsiloxane (Dimethicone); and, may further include 6 wt% to 16 wt% of water.
另外,本實施例中所使用的該水系潤滑劑較佳為至少包含有0.1~2.5wt%的三仙膠、0.1~4wt%的羥乙基纖維素、0.1~10wt%的甘油、0.001~10wt%玻尿酸、0.01~8wt%的鎖水磁石、檸檬酸0.01~3wt% 、0.01~4wt%的檸檬酸/氫氧化鈉、1~8wt%的戊二醇、以及6~97wt%的純水。In addition, the water-based lubricant used in this embodiment preferably contains at least 0.1-2.5wt% Sanxian gum, 0.1-4wt% hydroxyethyl cellulose, 0.1-10wt% glycerin, 0.001-10wt% % hyaluronic acid, 0.01~8wt% water-locking magnet, 0.01~3wt% citric acid, 0.01~4wt% citric acid/sodium hydroxide, 1~8wt% pentylene glycol, and 6~97wt% pure water.
然後,進行該軟質膠囊M1至M5的體外溶離測試。Then, the in vitro dissolution test of the soft capsules M1 to M5 was carried out.
配製濃度為50mM的磷酸鹽緩衝溶液500ml,並將pH值調整為4.0、溶液溫度調整為37℃,藉以模擬人體陰道環境。接著,使用全自動 8 槽溶離系統 (Agilent Technologies 708-DS Dissolution Apparatus),將軟質膠囊M1至M5分別放置於磷酸鹽緩衝溶液中,觀察軟質膠囊M1至M5的殼體溶解時間,並換算其溶解速率。Prepare 500ml of phosphate buffer solution with a concentration of 50mM, adjust the pH value to 4.0, and adjust the solution temperature to 37°C to simulate the human vaginal environment. Next, using a fully automatic 8-tank dissolution system (Agilent Technologies 708-DS Dissolution Apparatus), place the soft capsules M1 to M5 in phosphate buffer solution respectively, observe the shell dissolution time of the soft capsules M1 to M5, and convert their dissolution rate.
由上表1的結果可知,軟質膠囊形成用組合物S1至S5的黏度依序為10厘泊、18厘泊、26厘泊、34厘泊、45厘泊,凝膠強度依序為150Bloom、350Bloom、878Bloom、1954Bloom、2500Bloom;再者,軟質膠囊M1至M5的溶解時間依序為5.8分鐘、6.4分鐘、7.6分鐘、10.7分鐘、11.3分鐘,溶解速率依序為0.207g/min、0.188g/min、0.158g/min、0.112g/min、0.106g/min,顯示由實施例1中之軟質膠囊形成用組合物S1所製得的軟質膠囊M1具有最快的溶解速率。 As can be seen from the results in Table 1 above, the viscosities of compositions S1 to S5 for forming soft capsules are 10 centipoise, 18 centipoise, 26 centipoise, 34 centipoise, and 45 centipoise, and the gel strengths are 150 Bloom, Bloom, and S5 in sequence. 350Bloom, 878Bloom, 1954Bloom, 2500Bloom; moreover, the dissolution time of soft capsules M1 to M5 is 5.8 minutes, 6.4 minutes, 7.6 minutes, 10.7 minutes, 11.3 minutes, and the dissolution rate is 0.207g/min, 0.188g/min min, 0.158g/min, 0.112g/min, 0.106g/min, showing that the soft capsule M1 prepared from the soft capsule forming composition S1 in Example 1 has the fastest dissolution rate.
另外,在實施例1至5中,甘油(增塑劑)與甲基纖維素(增稠劑)的乾品總量相對於明膠乾品重量的比值依序為0.014、0.192、0.705、0.813、0.838,顯示當增塑劑與增稠劑的乾品總量相對於明膠乾品重量的比值越小時,軟質膠囊形成用組合物所製得的軟質膠囊之溶解速度越快,能夠藉由控制增塑劑與增稠劑的乾品總量相對於明膠乾品重量的比值來控制軟質膠囊之溶解時間及速度。 《實施例6》 In addition, in Examples 1 to 5, the ratio of the total amount of dry product of glycerin (plasticizer) and methylcellulose (thickener) relative to the weight of gelatin dry product is 0.014, 0.192, 0.705, 0.813, 0.838, showing that when the ratio of the total amount of dry product of plasticizer and thickener to the weight of gelatin dry product is smaller, the dissolution rate of the soft capsule prepared by the composition for forming a soft capsule is faster, which can be obtained by controlling the increase The ratio of the total amount of dry product of plasticizer and thickener to the weight of gelatin dry product controls the dissolution time and speed of the soft capsule. "Example 6"
在本實施例中,以實施例1所得的軟質膠囊形成用組合物S1製作成不同殼體厚度的軟質膠囊,並分析不同殼體厚度之軟質膠囊溶解時間,分析方式與前述實施例1至5相同,所得結果如表2所示。In this example, the composition S1 for forming soft capsules obtained in Example 1 was used to make soft capsules with different shell thicknesses, and the dissolution time of soft capsules with different shell thicknesses was analyzed. The analysis method was the same as that of Examples 1 to 5 above. Same, the obtained results are shown in Table 2.
表2
由上表2之結果可知,膠囊殼體破裂時間會隨著殼體厚度增加而增加,因此亦可視需求來調整殼體厚度以達到最佳使用效果。From the results in Table 2 above, we can see that the rupture time of the capsule shell will increase with the thickness of the shell, so the thickness of the shell can also be adjusted according to the needs to achieve the best use effect.
綜上所述,在如上所列舉的實施例中已經舉例而具體地說明本發明的內容了,然而本發明並非僅限定於此等實施方式而已。本發明所屬技術領域中具有通常知識者應當明白:在不脫離本發明的精神和範圍內,當可再進行各種的更動與修飾;例如,將前述實施例中所例示的各技術內容加以組合或變更而成為新的實施方式,此等實施方式也當然視為本發明所屬內容。因此,本案所欲保護的範圍也包括後述的申請專利範圍及其所界定的範圍。To sum up, the content of the present invention has been specifically described by way of examples in the above-listed embodiments, but the present invention is not limited to these embodiments. Those skilled in the technical field of the present invention should understand that various changes and modifications can be made without departing from the spirit and scope of the present invention; Changes can be made into new embodiments, and these embodiments should of course also be regarded as the content of the present invention. Therefore, the scope of protection in this case also includes the scope of the patent application and the scope defined thereafter.
100:膠囊型人體組織潤滑用栓劑 110:軟質膠囊 120:潤滑劑 100: Capsule type human tissue lubricating suppository 110: soft capsule 120: lubricant
圖1為顯示本發明之膠囊型人體組織潤滑用栓劑之示意圖。Fig. 1 is a schematic diagram showing the capsule type human tissue lubricating suppository of the present invention.
100:膠囊型人體組織潤滑用栓劑 100: Capsule type human tissue lubricating suppository
110:軟質膠囊 110: soft capsule
120:潤滑劑 120: lubricant
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW110124565A TWI787898B (en) | 2021-07-05 | 2021-07-05 | Composition for forming soft capsules, delayed-dissolving soft capsules using the same, and capsule-type human tissue lubricating suppositories |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW110124565A TWI787898B (en) | 2021-07-05 | 2021-07-05 | Composition for forming soft capsules, delayed-dissolving soft capsules using the same, and capsule-type human tissue lubricating suppositories |
Publications (2)
Publication Number | Publication Date |
---|---|
TWI787898B true TWI787898B (en) | 2022-12-21 |
TW202302075A TW202302075A (en) | 2023-01-16 |
Family
ID=85795126
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW110124565A TWI787898B (en) | 2021-07-05 | 2021-07-05 | Composition for forming soft capsules, delayed-dissolving soft capsules using the same, and capsule-type human tissue lubricating suppositories |
Country Status (1)
Country | Link |
---|---|
TW (1) | TWI787898B (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202106280A (en) * | 2019-08-08 | 2021-02-16 | 英諾美生物科技股份有限公司 | Capsule for storing lubricant |
-
2021
- 2021-07-05 TW TW110124565A patent/TWI787898B/en active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202106280A (en) * | 2019-08-08 | 2021-02-16 | 英諾美生物科技股份有限公司 | Capsule for storing lubricant |
Also Published As
Publication number | Publication date |
---|---|
TW202302075A (en) | 2023-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US12042559B2 (en) | Gastroretentive dosage forms for sustained drug delivery | |
JP7402911B2 (en) | Self-regulating osmotic gastroretentive drug delivery system | |
US20200165406A1 (en) | Polymer compositions | |
CN105342985B (en) | A kind of gel preparation and its application | |
JP2013100364A (en) | New composition for facilitating human delivery | |
Sánchez et al. | A novel double-layer mucoadhesive tablet containing probiotic strain for vaginal administration: Design, development and technological evaluation | |
WO2016020861A2 (en) | Vaginal composition for the treatment and prevention of urogenital infections, method for producing the same and uses thereof | |
US20200155621A1 (en) | Mucoadhesive sustained-release vaginal tablet | |
CA2875784C (en) | Pharmaceutical compositions containing oligomeric lactic acid | |
Ahmad et al. | Development and evaluation of an acid buffering bioadhesive vaginal gel for mixed vaginal infections | |
AU2022319690A1 (en) | Compositions And Techniques For Vaginal Insertion | |
TWI787898B (en) | Composition for forming soft capsules, delayed-dissolving soft capsules using the same, and capsule-type human tissue lubricating suppositories | |
CN107626001A (en) | A kind of medical sterilization lubricant and preparation method thereof | |
TW202106280A (en) | Capsule for storing lubricant | |
CN105997849B (en) | Water-soluble gynecological gel and preparation method thereof | |
RU2327465C1 (en) | Method of piglet's dysentery treatment | |
AHMAD et al. | Razvoj i in vitro vrednovanje puferiranog bioadhezivnog vaginalnog gela za miješane vaginalne infekcije | |
TW200528088A (en) | Composition of contraceptive woman disinfectant and manufacturing process thereof |